We show that co-targeting IGF1/insulin and LSD1 leads to significant antitumoral response not only in APL but also in other AML subtypes and triple-negative breast cancers, suggesting a therapeutic strategy. Here, IGF1 is linked to acute promyelocytic leukemia.